Forbes

WHO's 2026 Global Tuberculosis Report shows that over a million people died of TB in 2025, with worrisome drop in international donor funding

The Centers for Medicare and Medicaid Services final rule prevents manufacturers from resetting statutory drug price negotiation clocks through reformulations.

Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand

Healthsystems promise a doctor will catch AI errors. Studies show clinicians often follow wrong AI advice. A doctor explains when human review works and when it fails.

A once-daily oral peptide improved ulcerative colitis response and remission rates in a phase 2 trial, offering a potential alternative to injections or infusions.

A doctor breaks down the new FDA warning for GLP-1 drugs and how serious and common the eye condition is.

Anthropic’s recent purchase of one-man firm Mithril is just the tip of the spear in how it hopes to use AI to accelerate drug development as it seeks a $1.4 trillion valuation in the public markets.

Perhaps more than any other industry, health startups need established ecosystems of support. Here is a roundup of 27 top health accelerators around the country.

Could you start law school at 90? AI is helping scientists study how we age. More healthy years could change when we go back to school, start careers, and raise families.

Former New Orlean Saints quarterback Drew Brees discussed managing his food allergies that emerged early in his NFL career and what he's been up to since retiring.

The health and science professionals in Congress must defend scientific integrity, strengthen evidence-based policy, and put people's health ahead of party loyalty.

Staffing of physician practices and medical groups is falling again as the ongoing healthcare labor shortage worsens, The American Medical Group Association said.

Engineered T-cell therapy produced a deep response in a teenager with advanced kidney cancer, highlighting the promise and limits of personalized treatment.

The system makes the patient do too much. We divide care into specialities, then leave people to find their way across the gaps.